996 Asian patients undergoing TKA (1 study) and THA (second study) surgery were randomly assigned into 1 of 4 groups to determine if darexaban effectively and safely reduced the occurrence of venous thromboembolism (VTE) when compared to an oral placebo or subcutaneous enoxaparin. The four possible treatment methods were: a 15 or 30 mg oral dose of darexaban, a 20 mg subcutaneous injection of enoxaparin, or a placebo tablet. The results of the studies indicated that both doses of darexaban, 15 and 30 mg, were superior to the placebo, and comparable to enoxaparin when comparing total VTE incidence for either surgery. Results also demonstrated that incidence of bleeding was low across all treatment types, leading to very minimal, serious, adverse effects being experienced by patients.